MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By ...

By Michael Erman NEW YORK (Reuters) -Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in chemotherapy.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

Oncology is the company's most important field. It markets Keytruda, a cancer drug that topped the list of the world's best-selling drugs last year. Keytruda will run out of patent exclusivity in the ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

MSD’s subcutaneous (SC) Keytruda (pembrolizumab) has shown non-inferior pharmacokinetics (PK) to the intravenous (IV) version of the company’s blockbuster therapy in a pivotal trial.